Akorn (AKRX) Tops Q1 EPS by 10c, Guidance Tops Views, Announces Standstill Agreement
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Akorn Provides Preliminary First Quarter 2019 Results and Full Year Guidance
May 7, 2019 7:05 AM EDT-Operational improvements drive sequential growth-
-Full year outlook anticipates further sequential growth throughout the year-
LAKE FOREST, Ill., May 07, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced its preliminary financial results for the first quarter of 2019.
First Quarter 2019 and Recent Business Highlights
Net revenue was $166 million, up 8% from the fourth quarter of 2018, down 10% from the prior year quarterNet loss was $82 million, compared to $215 million in the fourth quarter of 2018 and... More